If you want a Stock Review on HOLX, NXTM, WMGI, or ABT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Pre-market today, DailyStockTracker.com has issued research reports on Hologic Inc. (NASDAQ: HOLX), Nxstage Medical Inc. (NASDAQ: NXTM), Wright Medical Group N.V. (NASDAQ: WMGI), and Abbott Laboratories (NYSE: ABT). Medical Appliances and Equipment firms research, develop, and manufacture primarily surgical, diagnostic, and orthopedic instruments. Daily Stock Tracker published free research reports on these stocks today at: http://dailystocktracker.com/register/
Marlborough, Massachusetts Hologic Inc.'s shares declined 0.93%, closing Wednesday's trading session at $39.25. The stock recorded a trading volume of 2.58 million shares. The Company's shares have advanced 6.63% in the last month and 3.43% over the previous three months. The stock is trading 3.93% above its 50-day moving average. Additionally, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, Asia/Pacific, and internationally, have a Relative Strength Index (RSI) of 57.61.
On November 06th, 2017, Hologic announced that it will present at the 29th Annual Piper Jaffray Healthcare Conference on November 29th, 2017, at 11:00 a.m. ET in New York. The presentation will be webcast live and may be accessed under the investors section of the Company's website. See our free and comprehensive research report on HOLX at: http://dailystocktracker.com/registration/?symbol=HOLX
On Wednesday, shares in Lawrence, Massachusetts headquartered Nxstage Medical Inc. recorded a trading volume of 268,462 shares. The stock declined 0.19%, ending the day at $25.82. The Company's shares are trading below their 200-day moving average by 2.19%. Furthermore, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 23.20.
On October 27th, 2017, Nxstage Medical (NXTM) announced that at a special meeting of stockholders held that day, the Company's stockholders voted to adopt the previously announced agreement and plan of merger, dated August 07th, 2017, with Fresenius Medical Care Holdings, Inc., whereby the latter will acquire NXTM through a wholly owned subsidiary of Fresenius. The approval of the merger agreement fulfills an important condition for the full acquisition of NXTM. NXTM free research report is just a click away at: http://dailystocktracker.com/registration/?symbol=NXTM
Wright Medical Group
Amsterdam, the Netherlands headquartered Wright Medical Group N.V.'s stock finished the day 2.24% higher at $24.21. A total volume of 1.34 million shares was traded, which was above their three months average volume of 1.01 million shares. The Company's shares have advanced 5.35% on an YTD basis. The stock is trading below its 50-day moving average by 7.38%. Additionally, shares of Wright Medical, which designs, manufactures, markets, and sells extremities and biologics products in the US, Europe, Middle-East, Africa, and internationally, an RSI of 39.99.
On November 07th, 2017, Wright Medical announced that it will present at the Piper Jaffray Healthcare Conference on November 28th, 2017, at the Lotte New York Palace Hotel in New York. Robert Palmisano, President and CEO, will present at 8:00 a.m. ET. A live audio webcast of the conference presentation, along with the accompanying presentation materials, will be available on the Company's website. Sign up for your complimentary report on WMGI at: http://dailystocktracker.com/registration/?symbol=WMGI
Shares in North Chicago, Illinois headquartered Abbott Laboratories ended yesterday's session 0.33% lower at $54.83. The stock recorded a trading volume of 5.00 million shares. The Company's shares have advanced 11.24% over the previous three months and 42.75% since the start of this year. The stock is trading 1.60% and 13.75% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Abbott Labs, which manufactures and sells health care products worldwide, have an RSI of 52.25.
On October 19th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $58 a share to $63 a share.
On November 06th, 2017, Abbott Laboratories announced that Japan's Ministry of Health, Labor, and Welfare has approved the Company's MitraClip device for treatment of people with mitral regurgitation (MR), a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward into the heart. MR causes many life-altering symptoms, and when left untreated, can ultimately lead to heart failure and death. Register for free on DailyStockTracker.com and download the latest research report on ABT at: http://dailystocktracker.com/registration/?symbol=ABT
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Powered by WPeMatico